This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Belgium
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies
ActoGeniX is a biopharmaceutical company focused on the development and commercialization of ActoBiotics?, a novel class of orally available biologicals for the treatment of GI, mucosal, immunological, and allergic diseases.
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. The Company's lead candidate, AMA0076, targets glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness.
Apitope is a privately owned European biotech company developing antigen specific therapeutic peptides for the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves? disease, Uveitis, and others. Company is currently developing peptide based therapeutics designed to selectively suppress this aberrant interaction between immune cell and protein antigen, reinstating the body?s natural immune tolerance to the body?s own proteins.
BETA-CELL is a privately owned biopharmaceutical company that develops novel cell therapy and other products related to Diabetes. Company's lead product, BetaGraft
Bioxodes goal is to develop a range of pharmaceutical and other bioscience products derived from natural sources.
The company?s initial focus is Ir-CPI, a unique contact phase inhibitor peptide having a range of potential applications in thrombosis, vascular permeability and complement activation. In thrombosis, the molecule has the potential to deliver a remarkable and unprecedented balance between antithrombotic benefit and hemorrhagic side effect.
The company?s initial focus is Ir-CPI, a unique contact phase inhibitor peptide having a range of potential applications in thrombosis, vascular permeability and complement activation. In thrombosis, the molecule has the potential to deliver a remarkable and unprecedented balance between antithrombotic benefit and hemorrhagic side effect.
Bone Therapeutics is an international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases. Utilizing the Company?s unique knowledge of the bone/joint physiology and long-standing expertise in cell therapy and cell transplantation, Bone Therapeutics has created a fully integrated business with an advanced product pipeline comprising novel bone cell products, tailored in-house production methods and minimally invasive treatment techniques.
Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Complix is a biopharmaceutical company spun out from Algonomics (now Lonza). Complix is set to transform the clinical utility of protein therapeutics with its revolutionary Alphabody? platform, by accessing a new universe of targets unavailable to current therapeutics approaches.
CuraVac is involved in the production of therapeutic vaccines for the treatment of autoimmune diseases. The company's first vaccine is ready for preliminary, Phase 1, human trials.
Euroscreen is a Belgium based, private Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including inflammation, neurodegenerative diseases and women?s diseases.
Euroscreen is advancing its orally-available and highly specific lead program ESN364 into clinical trials for women?s diseases such Endometriosis and Poly-Cystic Ovary Syndrome (PCOS). The Company is also actively seeking partners for other pharmaceutical candidates, such as its ESN282 program for the treatment of inflammatory diseases such as Ulcerative Colitis.
Euroscreen also has a dedicated business providing fee-for-service drug candidate testing (Euroscreen FAST ) for biopharmaceutical companies worldwide.
Euroscreen is advancing its orally-available and highly specific lead program ESN364 into clinical trials for women?s diseases such Endometriosis and Poly-Cystic Ovary Syndrome (PCOS). The Company is also actively seeking partners for other pharmaceutical candidates, such as its ESN282 program for the treatment of inflammatory diseases such as Ulcerative Colitis.
Euroscreen also has a dedicated business providing fee-for-service drug candidate testing (Euroscreen FAST ) for biopharmaceutical companies worldwide.
Formac Pharmaceuticals NV is a drug delivery company offering unique silica-based technology to enhance the oral bioavailability of poorly water-soluble active pharmaceutical ingredients. The company?s drug delivery technologies include CMO, an ordered mesoporous silica-based carrier material that enables the release of poorly soluble drug compounds.